XmAb412

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Comparator or background therapy1 trial
Phase 1	NCT07713485 Comparator	Jul 2026 → May 2027 expected	—	Xencor, Inc.	Recruiting	No outcome recorded

Date	Issuer	Release
2026-05-04	Xencor, Inc.	Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW xencor.com ↗

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	XmAb412	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07713485 ↗
Modality	Monoclonal antibody	“Monoclonal Bispecific Antibody” NCT07713485 ↗
Route	Intravenous	“using subcutaneous (SC) or intravenous (IV) administration route.” NCT07713485 ↗
Route	Subcutaneous	“using subcutaneous (SC) or intravenous (IV) administration route.” NCT07713485 ↗